Valuation: Centogene N.V.

Market Cap 2.61M 3.01M 2.44M 2.24M 4.22M 287M 4.28M 28.59M 11.22M 143M 11.29M 11.05M 476M P/E 2022
-2.24x
P/E 2023 -2.1x
Enterprise Value 63.85M 73.58M 59.79M 54.69M 103M 7.01B 105M 699M 275M 3.5B 276M 270M 11.66B EV / Sales 2022
2.03x
EV / Sales 2023 2.79x
Free-Float
95.16%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer - 2025-02-03
Director of Finance/CFO - -
Chief Operating Officer 56 2015-12-31
Director TitleAgeSince
Chairman 59 2017-06-30
Director/Board Member 48 2018-12-31
Director/Board Member 70 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.79M
-2.64%+1.57%-15.71%+39.55% 563B
-0.69%+0.71%-37.47%+70.74% 309B
+3.36%+0.14%-21.02%+55.91% 139B
-13.32%+21.40%+591.38%+2,024.86% 104B
-0.94%+3.26%-18.47%+30.29% 101B
-1.48%-9.10%-28.75%+229.64% 99.14B
-0.56%-0.29%+16.20%+8.18% 90.5B
+2.89%+7.96%-17.37%+155.10% 90.31B
-2.07%+2.51%-21.73%+27.12% 41.47B
Average -1.46%+0.32%+49.67%+293.49% 170.83B
Weighted average by Cap. -1.60%+1.85%+20.92%+197.26%

Financials

2022 2023
Net sales 47.47M 54.71M 44.45M 40.66M 76.77M 5.21B 77.77M 520M 204M 2.6B 205M 201M 8.67B 48.54M 55.93M 45.45M 41.57M 78.49M 5.33B 79.51M 532M 209M 2.66B 210M 205M 8.86B
Net income -31.84M -36.69M -29.82M -27.27M -51.49M -3.5B -52.16M -349M -137M -1.75B -138M -135M -5.81B -35.53M -40.94M -33.27M -30.44M -57.46M -3.9B -58.21M -389M -153M -1.95B -154M -150M -6.49B
Net Debt 24.17M 27.85M 22.63M 20.7M 39.09M 2.65B 39.6M 265M 104M 1.33B 105M 102M 4.41B 61.24M 70.57M 57.34M 52.46M 99.03M 6.72B 100M 671M 263M 3.36B 265M 259M 11.18B
Logo Centogene N.V.
Crown LiquidationCo NV in liquidatie, is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Employees
384